药物对比
Eptinezumab vs Fremanezumab
Eptinezumab（Vyepti）和 Fremanezumab（Ajovy）是靶向 CGRP 用于偏头痛预防的单克隆抗体。Eptinezumab 每 3 个月 IV 一次，Fremanezumab 每 1 个月/每 3 个月 SC 一次。安全性和疗效相似；选择取决于给药偏好。
此页面暂无可用的对比维度。
临床背景
Migraine patients seeking CGRP monoclonal antibody therapy often compare Eptinezumab and Fremanezumab to choose the optimal preventive option.
结论
Both Eptinezumab and Fremanezumab are effective CGRP inhibitors for migraine prevention, but the better option depends on individual factors like administration route and frequency.
全部药物对比